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Reclamation of Ampicillin Sensitivity for the Genetic Manipulation of
Legionella pneumophila
Molly C. Sutherland and Joseph P. Vogel

Research on Legionella pneumophila, the causative agent of Legionnaires’ disease, has been hampered due to the lack of selectable markers for genetic manipulation. We report the construction of a mutant strain of L. pneumophila lacking loxA, a chromosomally encoded ␤-lactamase, that has enhanced sensitivity to ampicillin. Also described are a method for converting Legionella
strains to ampicillin sensitivity and conditions for utilizing bla as a selectable marker.

L

egionellae are ubiquitous freshwater bacteria that are able to
replicate within protozoa in the environment and can also
grow inside alveolar macrophages (6, 8, 12). Human infection can
lead to a form of pneumonia called Legionnaires’ disease, which
was first identified during an outbreak at an American Legion
convention held in Philadelphia, PA, in 1976 (17). Legionnaires’
disease was traditionally treated with the macrolide erythromycin,
and more recently with fluoroquinolones, due to their membrane-permeant nature and the absence of drug resistance (6, 12–
14, 19). In contrast, ␤-lactams are not used to treat Legionnaires’
disease, congruent with the observation that Legionella pneumophila strains commonly display a low level of resistance to ␤-lactams in vitro and are highly resistant in vivo (3, 7, 10, 15, 18, 22).
Consistent with this result, it has recently been shown that
many Legionella species encode at least one ␤-lactamase. For example, the L. pneumophila strain Philadelphia I was shown to
encode a single class D ␤-lactamase, loxA (Legionella oxacillinase)
(2), which is homologous to the well-characterized ␤-lactamase
OXA-29 in Legionella gormanii (5, 9, 11, 16) (see Fig. S1 in the
supplemental material). loxA was proposed to be solely responsible for the ␤-lactamase activity present in the L. pneumophila
strain Philadelphia I, since lysates from this strain and from an
Escherichia coli strain expressing loxA contained a similar ␤-lactamase profile (2). However, since a strain lacking loxA had not been
constructed, it was not possible to definitively state that loxA was
accountable for all of the ␤-lactamase activity observed in this
strain.
Endogenous resistance to ampicillin of most L. pneumophila
strains has precluded the use of ␤-lactamase as a selectable marker
for basic research, thus compounding the lack of selectable markers currently available for L. pneumophila basic research. Thus,
with the goals of confirming that LoxA is responsible for the ␤-lactam resistance of the L. pneumophila Philadelphia I strain and
potentially developing an ampicillin-sensitive version of this
strain that could be used for genetic manipulation, we engineered
a ⌬loxA mutant in Lp02, a commonly used derivative of L. pneumophila Philadelphia I (see the supplemental Materials and Methods and Fig. S1 in the supplemental material) (4).
In order to determine if the loss of loxA increased the sensitivity
of a Legionella strain to ampicillin, the growth of strain Lp02
(JV4918) was compared with that of a ⌬loxA mutant (JV4921) on
plates containing increasing concentrations of ampicillin (0,
0.125, 0.25, 0.5, 1, 2, 4, and 10 g/ml ampicillin). Lp02 is resistant
to small amounts of ampicillin, and limited growth can be ob-
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served on plates containing 10 g/ml ampicillin (Fig. 1B, top left
quadrant). In contrast, a strain lacking loxA is quite sensitive to
ampicillin and cannot grow on plates having low levels of ampicillin (Fig. 1B, bottom left quadrant of plate containing 0.125
g/ml ampicillin). Similar results were observed when comparing
the growths of two additional commonly used L. pneumophila
strains, JR32 and AA100 (1, 20), with their corresponding loxA
deletions on plates containing ampicillin (data not shown).
Therefore, loxA appears to be solely responsible for the ampicillin
resistance of L. pneumophila Philadelphia I as previously proposed (2).
Having generated a strain with increased sensitivity to ampicillin, we examined whether ␤-lactamase (bla) could be used as a
selectable marker in L. pneumophila by comparing the growth of
the ⌬loxA mutant (JV4921) with that of the ⌬loxA mutant expressing bla from a plasmid (JV4920). In contrast with the ampicillin sensitivity of the ⌬loxA mutant without bla expression, expression of bla allowed the ⌬loxA mutant to form normal-sized
colonies on plates containing 0.5 to 1.0 g/ml ampicillin (Fig. 1B,
bottom right quadrant). It is worth noting that selection for a
bla-expressing plasmid was not feasible in the strain Lp02 as it
conferred only a slight increase in growth on ampicillin plates
(Fig. 1B, compare top left and top right quadrants). Based on these
results, we can conclude that the strain Lp02 is naturally resistant
to ampicillin, that deletion of loxA results in a strain that has
increased sensitivity to ampicillin, and that expression of bla in the
loxA deletion strain is able to restore ampicillin resistance, thus
allowing bla expression to be used as a selectable marker in this
Legionella background.
Since L. pneumophila grown in broth exhibits more-uniform
growth and infectivity than bacteria grown on solid medium,
broth-grown cultures are often preferentially used for experiments. Therefore, the replication of JV4921 (⌬loxA) and JV4920
(⌬loxA ⫹ bla) grown overnight in liquid medium containing increasing amounts of ampicillin was examined. Growth was mea-
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FIG 1 Ampicillin can be used as a selectable marker. (A and B) The strains

JV4918 (Lp02), JV4919 (Lp02 ⫹ bla), JV4920 (⌬loxA ⫹ bla), and JV4921
(⌬loxA) were streaked for isolated colonies on solid bacteriologic medium
containing 0, 0.125, 0.25, 0.5, 1, 2, 4, or 10 g/ml ampicillin. (C) JV4921
(squares) and JV4920 (triangles) were inoculated in liquid medium containing
2-fold dilutions of ampicillin ranging from 10 mg/ml to 0.002 g/ml. The
cultures were grown overnight, and the optical density at 600 nm (OD600) was
measured the next day. The data are representative of three independent experiments.

sured the next day by optical density readings at 600 nm (OD600)
and plotted as a function of ampicillin concentration (Fig. 1C).
Replication of JV4921 was completely inhibited by 0.125 g/ml
ampicillin, whereas full growth inhibition of JV4920 required
2,500 g/ml ampicillin (Fig. 1C). Moreover, JV4920 was able to
grow in the presence of up to 8 g/ml ampicillin at a rate comparable to that in the absence of the drug (Fig. 1C). Thus, 0.5 g/ml
ampicillin in plates and 5 g/ml ampicillin in broth are recommended as reasonable concentrations to select for a bla plasmid in
the ⌬loxA mutant.
Although 0.5 g/ml ampicillin in solid medium was sufficient
to inhibit the growth of the ⌬loxA mutant, it was worth determining if larger amounts of the drug could be used when selecting for
a bla-expressing plasmid during a transformation. To investigate
this, the plating efficiency of a ⌬loxA strain transformed with the
plasmid pJB1806, which confers both ampicillin and chloramphenicol resistance (Cmr), was examined. The number of transformants obtained on ampicillin plates was normalized to the
number observed on plates containing chloramphenicol (set to
100% in Fig. 2). Consistent with our previous results after streaking the bacteria for isolated colonies (Fig. 1B), 0.5 g/ml ampicillin did not affect the plating efficiency of the ⌬loxA strain expressing bla. However, increasing the ampicillin concentration 4- or
8-fold (to 2 or 4 g/ml) resulted in a significant decrease in the
plating efficiency of the strain (Fig. 2). Therefore, we recommend
using 0.5 g/ml ampicillin as the optimal concentration of the
drug to select for bla when transforming the L. pneumophila Lp02
⌬loxA strain.
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A key feature of Legionella virulence is the ability to replicate
within host cells, making it important to confirm that deleting
loxA did not indirectly affect intracellular survival and growth of
this pathogen. Replication was assayed within two host cells,
Acanthamoeba castellanii and A/J mouse-derived bone marrow
macrophages. Growths were compared for strain Lp02 (JV4933),
a ⌬loxA strain (JV4934), and a type IV secretion system-deficient
mutant (JV4936) (see Fig. S2 in the supplemental material). Fold
growth was monitored at defined time points by plating on charcoal yeast extract (CYE) plates supplemented with thymidine and
chloramphenicol (see Fig. S2A and C in the supplemental material) or ampicillin (see Fig. S2B and D in the supplemental material). Importantly, the ⌬loxA strain (JV4934) and the Lp02 strain
(JV4933) grew similarly, indicating that a strain lacking loxA is not
attenuated for intracellular growth. Moreover, the number of
CFU obtained on ampicillin plates was the same as that on chloramphenicol plates, demonstrating that ampicillin can function as
a new selectable marker for monitoring intracellular replication of
L. pneumophila.
Having demonstrated that bla can be used as a selectable
marker for L. pneumophila research, it was important to develop a
simple and efficient method for the construction of ampicillinsensitive strains. Our initial ⌬loxA strains used in this study were
constructed through a standard loop-in/loop-out procedure (see
the supplemental Materials and Methods in the supplemental material). Although this protocol is effective, it can be labor-intensive
and time-consuming. In contrast, construction of deletions by
natural transformation requires less work and is more rapid (21).
To optimize the natural transformation reaction, a ⌬loxA::Cmr
suicide plasmid (pJB3998) that contains 500 bp of DNA on
each side of the loxA locus was constructed and tested. Natural
transformations were performed as previously described (21)
and involved spotting DNA onto a newly made patch of L.
pneumophila, growing the strain for 2 days at 30°C, and streaking for isolation. By selecting for chloramphenicol resistance,
⌬loxA::Cmr transformants were obtained by natural transformation of Lp02 using 0.01 to 10 g of pJB3998 (Fig. 3). The
transformants were authentic, as spontaneous chlorampheni-
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FIG 2 Effects of ampicillin concentration on plating efficiency. A ⌬loxA strain
(JV3690) was transformed with 1 g of pJB1806 (ampicillin-resistant [Ampr],
Cmr plasmid). Transformants were plated on solid medium containing 0.25,
0.5, 1, 2, or 4 g/ml ampicillin or chloramphenicol. Transformation of a second plasmid, pJB908, was selected on plates lacking thymidine and used as an
independent control for transformation frequency. Plating efficiency on
ampicillin was determined by comparing growth on solid medium containing
ampicillin to growth on chloramphenicol. Transformations were done in triplicate, and the error bars represent the standard deviations from the mean.

Ampicillin Resistance in Legionella

used to culture this pathogen (7). Therefore, reclamation of ampicillin as an additional selectable marker will be useful in many of
the L. pneumophila strains that have been constructed in laboratories around the world.
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FIG 3 ⌬loxA natural transformants can be obtained at high frequencies using
a suicide plasmid containing 4 kb of DNA surrounding the loxA locus. pJB3998
(0.5 kb of flanking DNA) and pJB5283 (4 kb of flanking DNA) were used to
naturally transform Lp02 with increasing DNA concentrations of 0.01 to 10
g. Natural-transformation frequencies were determined by dividing the
number of natural transformants (Cmr) by the number of viable cells. The
numbers of transformants obtained with various amounts of DNA are shown
for pJB3998 (filled bars) and for pJB5283 (open bars). Transformations were
done in triplicate, and the error bars represent the standard deviations from
the mean.

col-resistant colonies were never detected when water was used
in the transformation reaction (Fig. 3).
Although transformants were obtained, frequencies higher
than 1/100,000 were not achieved, even when using 10 g of DNA.
This low frequency precludes the construction of an unmarked
deletion by this method because identification of the deletion
would be exceedingly laborious. As a result, a chloramphenicol
marked-natural transformation vector (pJB5283) that contained
4 kb of DNA flanking the loxA gene was made, as a previous report
indicated that lengthening the size of the homologous DNA resulted in higher transformation efficiencies (21). Significantly
more transformants were obtained using pJB5283 than using
pJB3998, resulting in a transformation frequency of approximately 4% when 10 g of pJB5283 was used (Fig. 3). This frequency should be sufficiently high to allow direct detection of an
integration of an unmarked vector in a natural transformation
reaction.
To confirm that an unmarked deletion can be made in one step
using this method, we repeated the natural transformations using
pJB3951, which is an unmarked ⌬loxA plasmid containing 4 kb of
homologous flanking DNA. Transformants were identified by
comparing growths on CYET plates with and without 0.5 g/ml
ampicillin. Using pJB3951, we have been able to achieve transformation efficiencies approaching 2.5%. This high level of integration will allow for the efficient identification of ⌬loxA transformants by a significantly faster method than the classical loop-in/
loop-out strategy, although the latter strategy can still be used in
strains that are not naturally competent. In addition, our protocol
is not dependent on leaving a second drug marker on the chromosome, a result discordant with the development of an additional
selectable marker.
In conclusion, unmarked deletions of loxA that are sensitive to
ampicillin can now be easily generated via a single step in naturally
competent forms of L. pneumophila. This will be beneficial to researchers studying Legionella pathogenesis, as only a few antibiotics (e.g., kanamycin and chloramphenicol) are commonly used in
the lab setting. This problem has been exacerbated by endogenous
resistance to some antibiotics and/or inactivation of some antibiotics, including tetracycline, by the charcoal-yeast extract medium
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